Zhou, Wenxian
Shi, Yifeng
Wang, Hui
Chen, Linjie
Yu, Caiyu
Zhang, Xufei
Yang, Lei
Zhang, Xiaolei http://orcid.org/0000-0003-0117-7599
Wu, Aimin
Article History
Received: 16 February 2022
Revised: 6 May 2022
Accepted: 9 May 2022
First Online: 26 July 2022
Competing interests
: The authors declare no competing interests.
: All experimental procedures in this study, such as surgery, treatment, and postoperative care of animals, followed the “Guidelines for the Care and Use of Laboratory Animals” issued by the National Institutes of Health. All animal experiments were approved by the Animal Care and Use Committee of Wenzhou Medical University. Genetically identified FNDC5-knockout (FNDC5<sup>−/−</sup>) mice with a C57BL/6 background were established by a commercial supplier (Cyagen Biosciences) using CRISPR/Cas9-mediated genome engineering as detailed in the supplementary information. No clinical trial was involved in this study.